In a filing, Nuvalent Inc revealed its Former Affiliate BCLS II INVESTCO, LP acquired Company’s shares for reported $0.35 million on Jul 24 ’25. In the deal valued at $82.08 per share,4,253 shares were bought.
Then, BCIP Life Sciences Associates, bought 156,670 shares, generating $12,859,474 in total proceeds.
Before that, Bain Capital Life Sciences Fun bought 1,286,344 shares. Nuvalent Inc shares valued at $105,583,116 were divested by the Former Affiliate at a price of $82.08 per share.
UBS upgraded its Nuvalent Inc [NUVL] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late December with a ‘”a Buy”‘ rating. UBS began covering NUVL with “Neutral” recommendation on October 24, 2024. Barclays started covering the stock on August 29, 2024. It rated NUVL as “an Overweight”.
Price Performance Review of NUVL
On Friday, Nuvalent Inc [NASDAQ:NUVL] saw its stock fall -0.82% to $81.41. Over the last five days, the stock has lost -2.39%. Nuvalent Inc shares have fallen nearly -1.33% since the year began. Nevertheless, the stocks have risen 4.00% over the past one year. While a 52-week high of $113.51 was reached on 02/06/25, a 52-week low of $55.53 was recorded on 04/09/25.
Levels Of Support And Resistance For NUVL Stock
The 24-hour chart illustrates a support level at 77.68, which if violated will result in even more drops to 73.96. On the upside, there is a resistance level at 83.63. A further resistance level may holdings at 85.86.
How much short interest is there in Nuvalent Inc?
A steep rise in short interest was recorded in Nuvalent Inc stocks on 2025-07-15, growing by 0.29 million shares to a total of 5.49 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 5.21 million shares. There was a rise of 5.19%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 17, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $97 price target.
